A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

BACKGROUND: Depressive disorders are a leading cause of disability, but current behavioural and pharmacological therapies have a slow onset of response, typically taking several weeks before achieving efficacy. Prior studies using triplicate intravenous scopolamine infusions have been shown to reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Joseph C. C., Sumner, Rachael L., Krishnamurthy Naga, Venkat, Hoeh, Nicholas, Ayeni, Hafis Adetokunbo, Singh, Vikrant, Sundram, Frederick, Campbell, Douglas, Muthukumaraswamy, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011244/
https://www.ncbi.nlm.nih.gov/pubmed/32041658
http://dx.doi.org/10.1186/s13063-020-4089-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011244/
https://www.ncbi.nlm.nih.gov/pubmed/32041658
http://dx.doi.org/10.1186/s13063-020-4089-6

Ejemplares similares